Role of biological agents inflammatory diseases

被引：29

作者：

Efthimiou, P ^{[1
]}

Markenson, JA ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA

来源：

SOUTHERN MEDICAL JOURNAL | 2005年 / 98卷 / 02期

关键词：

biological therapy; IL-1 receptor antagonist; psoriatic arthritis; rheumatoid arthritis; TNF-alpha inhibitors;

D O I：

10.1097/01.SMJ.0000153119.37032.8B

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new era in the treatment of immune-mediated inflammatory disorders has begun with the clinical availability of anticytokine therapy. Biological agents that are currently available include 3 agents that decrease the activity of tumor necrosis factor-alpha (infliximab, adalimumab, etanercept) and an interleukin-1 receptor antagonist (anakinra), with many more in development. Those extraordinarily effective medications are an important addition to our therapeutic armamentarium, and, although originally developed for rheumatoid arthritis and Crohn disease, have been found to be efficacious in the treatment of seronegative spondyloarthropathies (psoriatic arthritis, ankylosing spondylitis) and juvenile rheumatoid arthritis. Their role is currently being defined in other autoimmune disorders such as uveitis, sarcoidosis, interstitial lung disease, vasculitis, inflammatory myopathies, graft-versus-host disease, and Sjogren syndrome.

引用

页码：192 / 204

页数：13

共 105 条

[1]

AMGEN, 2001, KINERET ANAKINRA PRE

[2]

Antoni C, 2002, ARTHRITIS RHEUM-US, V46, pS381

[3]

Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS122

[4] Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation [J].

Antoni, C ;

Dechant, C ;

Lorenz, PDHM ;

Wendler, J ;

Ogilvie, A ;

Lueftl, M ;

Kalden-Nemeth, D ;

Kalden, JR ;

Manger, B .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (05) :506-512

[5] BIOLOGICAL PROPERTIES OF RECOMBINANT HUMAN MONOCYTE-DERIVED INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].

AREND, WP ;

WELGUS, HG ;

THOMPSON, RC ;

EISENBERG, SP .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1694-1697

[6] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[7] The tumor necrosis factor ligand and receptor families [J].

Bazzoni, F ;

Beutler, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1717-1725

[8]

Brahn E, 2003, ARTHRITIS RHEUM, V48, pS676

[9] Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].

Brandt, J ;

Khariouzov, A ;

Listing, J ;

Haibel, H ;

Sörensen, H ;

Grassnickel, L ;

Rudwaleit, M ;

Sieper, J ;

Braun, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675

[10] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

← 1 2 3 4 5 6 7 8 9 10 →